IBDEI0AE ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4479,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4479,1,4,0)
 ;;=4^596.54
 ;;^UTILITY(U,$J,358.3,4479,1,5,0)
 ;;=5^Neurogenic Bladder 
 ;;^UTILITY(U,$J,358.3,4479,2)
 ;;=^304798
 ;;^UTILITY(U,$J,358.3,4480,0)
 ;;=788.43^^23^231^11
 ;;^UTILITY(U,$J,358.3,4480,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4480,1,4,0)
 ;;=4^788.43
 ;;^UTILITY(U,$J,358.3,4480,1,5,0)
 ;;=5^Nocturia
 ;;^UTILITY(U,$J,358.3,4480,2)
 ;;=^84740
 ;;^UTILITY(U,$J,358.3,4481,0)
 ;;=590.00^^23^231^14
 ;;^UTILITY(U,$J,358.3,4481,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4481,1,4,0)
 ;;=4^590.00
 ;;^UTILITY(U,$J,358.3,4481,1,5,0)
 ;;=5^Pyelonephritis, Chronic
 ;;^UTILITY(U,$J,358.3,4481,2)
 ;;=^270367
 ;;^UTILITY(U,$J,358.3,4482,0)
 ;;=788.41^^23^231^17
 ;;^UTILITY(U,$J,358.3,4482,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4482,1,4,0)
 ;;=4^788.41
 ;;^UTILITY(U,$J,358.3,4482,1,5,0)
 ;;=5^Urinary Frequency
 ;;^UTILITY(U,$J,358.3,4482,2)
 ;;=^124396
 ;;^UTILITY(U,$J,358.3,4483,0)
 ;;=788.20^^23^231^19
 ;;^UTILITY(U,$J,358.3,4483,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4483,1,4,0)
 ;;=4^788.20
 ;;^UTILITY(U,$J,358.3,4483,1,5,0)
 ;;=5^Urinary Retention
 ;;^UTILITY(U,$J,358.3,4483,2)
 ;;=^295812
 ;;^UTILITY(U,$J,358.3,4484,0)
 ;;=600.01^^23^231^1
 ;;^UTILITY(U,$J,358.3,4484,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4484,1,4,0)
 ;;=4^600.01
 ;;^UTILITY(U,$J,358.3,4484,1,5,0)
 ;;=5^BPH w/ Obstruction
 ;;^UTILITY(U,$J,358.3,4484,2)
 ;;=^329933
 ;;^UTILITY(U,$J,358.3,4485,0)
 ;;=600.00^^23^231^2
 ;;^UTILITY(U,$J,358.3,4485,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4485,1,4,0)
 ;;=4^600.00
 ;;^UTILITY(U,$J,358.3,4485,1,5,0)
 ;;=5^BPH w/o Obstruction
 ;;^UTILITY(U,$J,358.3,4485,2)
 ;;=^334276
 ;;^UTILITY(U,$J,358.3,4486,0)
 ;;=595.9^^23^231^4
 ;;^UTILITY(U,$J,358.3,4486,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4486,1,4,0)
 ;;=4^595.9
 ;;^UTILITY(U,$J,358.3,4486,1,5,0)
 ;;=5^Cystitis
 ;;^UTILITY(U,$J,358.3,4486,2)
 ;;=^30304
 ;;^UTILITY(U,$J,358.3,4487,0)
 ;;=585.6^^23^231^6
 ;;^UTILITY(U,$J,358.3,4487,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4487,1,4,0)
 ;;=4^585.6
 ;;^UTILITY(U,$J,358.3,4487,1,5,0)
 ;;=5^End Stage Renal Disease
 ;;^UTILITY(U,$J,358.3,4487,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,4488,0)
 ;;=592.0^^23^231^8
 ;;^UTILITY(U,$J,358.3,4488,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4488,1,4,0)
 ;;=4^592.0
 ;;^UTILITY(U,$J,358.3,4488,1,5,0)
 ;;=5^Kidney Stone
 ;;^UTILITY(U,$J,358.3,4488,2)
 ;;=^67056
 ;;^UTILITY(U,$J,358.3,4489,0)
 ;;=590.01^^23^231^15
 ;;^UTILITY(U,$J,358.3,4489,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4489,1,4,0)
 ;;=4^590.01
 ;;^UTILITY(U,$J,358.3,4489,1,5,0)
 ;;=5^Pyelonephritis,Chr w/ Med Nec
 ;;^UTILITY(U,$J,358.3,4489,2)
 ;;=^270368
 ;;^UTILITY(U,$J,358.3,4490,0)
 ;;=584.9^^23^231^16
 ;;^UTILITY(U,$J,358.3,4490,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4490,1,4,0)
 ;;=4^584.9
 ;;^UTILITY(U,$J,358.3,4490,1,5,0)
 ;;=5^Renal Failure,Acute
 ;;^UTILITY(U,$J,358.3,4490,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,4491,0)
 ;;=233.7^^23^232^12
 ;;^UTILITY(U,$J,358.3,4491,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4491,1,4,0)
 ;;=4^233.7
 ;;^UTILITY(U,$J,358.3,4491,1,5,0)
 ;;=5^Ca In-Situ Bladder
 ;;^UTILITY(U,$J,358.3,4491,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,4492,0)
 ;;=233.0^^23^232^13
 ;;^UTILITY(U,$J,358.3,4492,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4492,1,4,0)
 ;;=4^233.0
 ;;^UTILITY(U,$J,358.3,4492,1,5,0)
 ;;=5^Ca In-Situ Breast
 ;;^UTILITY(U,$J,358.3,4492,2)
 ;;=Ca In-Situ Breast^267735
 ;;^UTILITY(U,$J,358.3,4493,0)
 ;;=233.1^^23^232^14
 ;;^UTILITY(U,$J,358.3,4493,1,0)
 ;;=^358.31IA^5^2
